drugset / Trial / NCT01564277
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Phase 2
Terminated
24 enrolled
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of rasburicase is more effective in treating hematologic malignancies when given together with or without allopurinol.
Timeline
- Start
- 2011-09-29
- Primary completion
- 2015-05-28
- Completion
- 2016-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rasburicase | Protein / enzyme biologic | 1.5 mg | Intravenous |
| Subject | Rasburicase | Protein / enzyme biologic | 3 mg | Intravenous |
| Background | Allopurinol | Small molecule | — | Oral |
Indications
Burkitt lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia with 11q23 abnormalities
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
acute myeloid leukemia with t(8;21)(q22;q22) translocation
blast phase chronic myelogenous leukemia, BCR-ABL1 positive
myelodysplastic syndrome